title: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
abstract: BACKGROUND
  Doxorubicin (D) (Adriamycin) is a potent and efficacious chemotherapeutic agent in the treatment of various forms of cancer, but its use has been limited by the development of cardiac toxicity. Historically, D-induced cardiomyopathy (CMP) has been refractory to therapy. We report our experience with this form of CMP at the University of Alabama at Birmingham.
  
  
  METHODS
  Twenty-five patients (20 women, 5 men) with a clinical diagnosis of D-CMP were referred to our program from 1990 to 2003. Patient data were extracted from office charts.
  
  
  RESULTS
  Patients were followed-up for 71 +/- 58 months. On presentation, the average left ventricular ejection fraction (LVEF) was 26 +/- 9.2%, and 88% of patients were New York Heart Association (NYHA) Class III or IV. Patients were treated with angiotensin-converting enzyme inhibitors (ACEi; n = 23) or angiotensin-receptor blocker (ARB; n = 2), and 15 were treated with a combination of ACEi and beta-blockers (BB). With medical therapy, LVEF improved significantly (26 +/- 9.2% vs 35 +/- 16.5%, p = 0.022), as did the NYHA class (p < 0.003). All survivors (n = 19) were NYHA Class I or II with medical therapy, with 10 (53%) being Class I. In the group of patients treated with ACEi + BB, there was a statistically significant improvement in LVEF (26 +/- 10.0% vs 37 +/- 17.6%, p = 0.028), which not seen in the ACEi group, with a strong trend toward normalization of LV function (47% vs 10%, p = 0.054).
  
  
  CONCLUSIONS
  In the current era of management of heart failure, D-CMP carries a better prognosis than previously described. Early addition of BB may further improve LVEF.
authors.affiliation: Department of Medicine, Birmingham VA Medical Center, Birmingham, Alabama 35294, USA. jtallaj@uab.edu
authors.forename: José A
authors.initials: JA
authors.lastname: Tallaj
authors.forename: Verónica
authors.initials: V
authors.lastname: Franco
authors.forename: Barry K
authors.initials: BK
authors.lastname: Rayburn
authors.forename: Laura
authors.initials: L
authors.lastname: Pinderski
authors.forename: Raymond L
authors.initials: RL
authors.lastname: Benza
authors.forename: Salpy
authors.initials: S
authors.lastname: Pamboukian
authors.forename: Brian
authors.initials: B
authors.lastname: Foley
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bourge
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013318:Stroke Volume; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin